Aerie pharmaceuticals announces presentation at the ophthalmology innovation summit dry eye innovation showcase

Durham, n.c.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that david a. hollander, m.d., m.b.a., chief research & development officer presented an overview on ar-15512, aerie's dry eye product candidate, at the ophthalmology innovation
AERI Ratings Summary
AERI Quant Ranking